Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovia AB ( (SE:IMMNOV) ) just unveiled an update.
Immunovia has partnered with Leiden University Medical Center to conduct a clinical validation study of its PancreaSure test, aimed at individuals with the CDKN2A genetic mutation, which significantly increases the risk of pancreatic cancer. This study is expected to enhance the clinical evidence supporting PancreaSure, aiding in regulatory submissions and reimbursement efforts, and is part of Immunovia’s broader strategy to commercially launch the test in the U.S. market by September 2025.
More about Immunovia AB
Immunovia AB is a diagnostic company dedicated to improving survival rates for pancreatic cancer patients through early detection. The company focuses on developing and commercializing blood-based tests to detect proteins and antibodies indicative of pancreatic cancer, collaborating with healthcare providers, experts, and patient advocacy groups to make these tests accessible to high-risk individuals.
Average Trading Volume: 3,795,041
Current Market Cap: SEK118.9M
For detailed information about IMMNOV stock, go to TipRanks’ Stock Analysis page.